Scholarlink

<p>Kawasaki disease (KD) is a childhood vasculitis with common pediatric ailments features. The KD coronary tropism and delayed diagnosis lead to long-term consequences. A 42-question web-based survey, developed in collaboration with the KD Arab Initiative (Kawarabi), covered pediatricians in charge of KD across major Moroccan cities. Responses from 18/23 (78%) contacts covered 12 universities and 2 public health hospitals, and 4 private practices. Main responders (9 pediatricians, 3 pediatric cardiologists, 2 pediatric and adult cardiologists, and 2 pediatric rheumatologists) follow the European (55.6%), the American (27.8%) guidelines, or local consensus recommendations (16.6%). First-line treatment was intravenous immunoglobulin (88.8%), or corticosteroids (5.5%) or acetyl salicylic acid (5.5%) monotherapy. On a scale from 1 to 10, KD knowledge was rated high (5 to 8) among the medical community, but low (1 to 4) in the general population. There was inequity in access to care and treatment options, varying from almost impossible to excellent. Post-discharge follow-up was carried out by pediatricians (77.7%), with access to pediatric cardiology (61.1%). Anticoagulation was available (88.8%) using anti-vitamin K or low-molecular-weight-heparin. A 10-year expert opinion estimate of KD shock syndrome, giant coronary aneurysms, myocardial ischemia or acute coronary syndrome, and coronary artery bypass grafts, totaled 62, 74, 13, and 9, respectively. KD remains a challenge in Morocco despite dedicated professionals. National seminars and collaborative research initiatives can be optimized with international engagements. Adherence to standardized diagnostic and treatment protocols, making intravenous immunoglobulin availability a national priority requires partnership with government agencies and healthcare officials.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Access to Care and Therapy for Kawasaki Disease in Morocco: A Kawasaki Disease Arab Initiative (Kawarabi) Multicenter Survey

  • 期刊论文

  • 发表日期：

    2026年1月19日

查看全文
  • Kenza Bouayed,
  • Sara Ahchouch,
  • Maryam Jalal,
  • Bouchra Chkirate,
  • Nadia Mebrouk,
  • Noureddine Rada,
  • Mohamed Bouskraoui,
  • Abdenasser Drighil,
  • Hamza Benjelloun,
  • Hafsa Moukhane,
  • Moustapha Hida,
  • Safaa Hajjaj,
  • Abdellatif Daoudi,
  • Sifeddine Nejmi,
  • Said Chraibi,
  • Amine Essaidi,
  • Myriam Bensemlali,
  • Dalal Ansar El Hamraoui,
  • Amal Fadil,
  • Kaoutar Khabbache,
  • Abdeladim Babakhouya,
  • Nadia El Idrissi Slitine,
  • Raed Alzyoud,
  • Ashraf Harahsheh,
  • Nadine Choueiter,
  • Nagib Dahdah

摘要

Kawasaki disease (KD) is a childhood vasculitis with common pediatric ailments features. The KD coronary tropism and delayed diagnosis lead to long-term consequences. A 42-question web-based survey, developed in collaboration with the KD Arab Initiative (Kawarabi), covered pediatricians in charge of KD across major Moroccan cities. Responses from 18/23 (78%) contacts covered 12 universities and 2 public health hospitals, and 4 private practices. Main responders (9 pediatricians, 3 pediatric cardiologists, 2 pediatric and adult cardiologists, and 2 pediatric rheumatologists) follow the European (55.6%), the American (27.8%) guidelines, or local consensus recommendations (16.6%). First-line treatment was intravenous immunoglobulin (88.8%), or corticosteroids (5.5%) or acetyl salicylic acid (5.5%) monotherapy. On a scale from 1 to 10, KD knowledge was rated high (5 to 8) among the medical community, but low (1 to 4) in the general population. There was inequity in access to care and treatment options, varying from almost impossible to excellent. Post-discharge follow-up was carried out by pediatricians (77.7%), with access to pediatric cardiology (61.1%). Anticoagulation was available (88.8%) using anti-vitamin K or low-molecular-weight-heparin. A 10-year expert opinion estimate of KD shock syndrome, giant coronary aneurysms, myocardial ischemia or acute coronary syndrome, and coronary artery bypass grafts, totaled 62, 74, 13, and 9, respectively. KD remains a challenge in Morocco despite dedicated professionals. National seminars and collaborative research initiatives can be optimized with international engagements. Adherence to standardized diagnostic and treatment protocols, making intravenous immunoglobulin availability a national priority requires partnership with government agencies and healthcare officials.